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ABSTRACT
The WHO Global Influenza Surveillance Network has
routinely performed genetic and antigenic analyses
of human influenza viruses to monitor influenza
activity. Although these analyses provide supporting
data for the selection of vaccine strains, it seems
desirable to have user-friendly tools to visualize
the antigenic evolution of influenza viruses for the
purpose of surveillance. To meet this need, we have
developed a web server, ATIVS (Analytical Tool
for Influenza Virus Surveillance), for analyzing sero-
logical data of all influenza viruses and hemaggluti-
nin sequence data of human influenza A/H3N2
viruses so as to generate antigenic maps for influ-
enza surveillance and vaccine strain selection.
Functionalities are described and examples are
provided to illustrate its usefulness and perfor-
mance. The ATIVS web server is available at http://
influenza.nhri.org.tw/ATIVS/.
INTRODUCTION
Inﬂuenza viruses cause substantial medical and social bur-
dens worldwide. Vaccination is the primary method to
prevent inﬂuenza and its complications. Hemagglutinin
(HA) of inﬂuenza viruses is the main surface protein indu-
cing protective antibody responses. The HA protein is
synthesized as a single polypeptide (HA0), which is subse-
quently cleaved into two polypeptides, HA1 and HA2,
and forms into homotrimers. The HA1 mutates more
frequently than the HA2 and plays a major role in the
process of natural selection (1,2). Accumulation of point
mutations on the HA result in antigenic drift, so that anti-
body raised in response to one virus may have reduced
eﬀectiveness against a drifted virus. Since 1977, inﬂuenza
A/H1N1, A/H3N2 and B viruses have been circulating
globally, and thus current vaccines are usually trivalent,
containing these three strains.
In order to tackle the seasonal epidemics of inﬂuenza,
the WHO Global Inﬂuenza Surveillance Network was
established in 1952 (http://www.who.int/csr/disease/
inﬂuenza/surveillance/). The collaborative centres in the
network perform antigenic and genetic analyses of viral
isolates regularly. Antigenic characterization of inﬂuenza
viruses is based on hemagglutinin-inhibition (HI) tests
using ferret antisera. Cross-reactive HI titers among refer-
ence antisera and circulating viruses are summarized into
tables. To utilize the information in these tables sensibly,
Smith et al. (2) presented a quantitative relationship for
mapping antigenic evolution of inﬂuenza viruses (cartog-
raphy), but the cartography software does not seem to be
available for public use. Another eﬀort to monitor the
changes in the surface antigens of inﬂuenza viruses starts
with analyzing sequence data in viral RNA genes contain-
ing the antigenic regions (the HA1 domain). Examining
the relationship between the sequence changes and the
antigenic diﬀerences of these viruses, Lee et al. (3) and
Liao et al. (4) identiﬁed some potential immunodominant
positions and proposed statistical models for predicting
antigentic variants of inﬂuenza A/H3N2 viruses on the
basis of sequence information.
In this study, we present a web server ATIVS
(Analytical Tool for Inﬂuenza Virus Surveillance) to ana-
lyze serological data of inﬂuenza viruses and provide
easily interpretive summaries; to compare the HA1
sequences of viruses with those of reference vaccine strains
to predict inﬂuenza A/H3N2 antigenic distances; based on
the serological data and the predicted antigenic distances,
to generate antigenic maps, which further demonstrate the
antigenic evolution of inﬂuenza viruses and facilitate the
selection of vaccine strains.
OVERVIEW
ATIVS has functionalities including analyzing serology
data for all inﬂuenza subtypes and HA1 sequence data
for inﬂuenza A/H3N2 viruses. After inputting a serologi-
cal table, antigenicity analysis is performed to show
two supporting ﬁgures along with an easily interpretive
table. Subsequently, an antigenic map can be generated
after parameter setting. When the serological data
are not available and only amino-acid sequence data are
available, antigenic prediction models are implemented to
predict antigenic distances based on the diﬀerences of
*To whom correspondence should be addressed. Tel: +886 37 246 166. Ext. 36100; Fax: +886 37 586 467; Email: hsiung@nhri.org.tw
Correspondence may also be addressed to Min-Shi Lee. Tel: +886 37 246 166. Ext. 37742; Fax: +886 37 583 009; Email: minshi.lee@hotmail.com
 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.amino-acid sequences; after that, the antigenicity analysis
is performed and an antigenic map is constructed as
previously described. The ﬂowchart of ATIVS is shown
in Figure 1. Notably, the subﬁgures presented in the
Figure 1 were generated from diﬀerent example data;
details can be found in the ﬁgure legend.
FUNCTIONALITIES
Serological data analysis
Given a serological table that describes cross-reactive
titers between antigens of circulating and reference strains
and antisera of reference strains, we calculate ratios
between homologous and heterologous antibody titers
(Figure 1a); ratios of antibody titers <4 are deﬁned as
similar antigenicity between the reference and circulating
strains and ratios  4 are deﬁned as low-reactors or anti-
gen variants to the reference strains (3,4). Based on the
ratios of antibody titers in the serological table, we would
know if any reference strains are similar to the circulating
strains (3,4). From these, an easily interpretive table
is summarized and downloadable. Besides, two supporting
ﬁgures are provided as bar and pie charts to summarize
the antigenic relationship (Figure 1b). The bar chart is to
determine which reference strains provide optimal anti-
genic coverage rate against the circulating strains.
Alternatively, the pie chart demonstrates the antigenicity
distribution of the circulating strains that can be covered
by the reference strains (single, multiple or low-reactors to
all). Take the example in the serology data input (as
shown in Figure 1a) for illustration. The antigenic cover-
age rate of the antiserum of A/California/7/2004 against
the circulating viruses is about 57% (Figure 1b), with
21% solely reacted to the antiserum of A/California/7/
2004 and 36% reacted to multiple antisera (Figure 1b).
Based on this kind of serological table including recent
circulating viruses versus contemporary vaccine strains
and potential reference strains, the two supporting ﬁgures
provided by antigenicity analysis help us to determine
which reference strains can be selected as vaccine candi-
dates. The viruses with both high antigenic coverage rate
and antigenic uniqueness are selected as vaccine strain
candidates.
Subsequently, the serological data can be used to
construct a 2D antigenic map (2), as shown in Figure 1c.
The construction procedure is detailed in the following
subsection on sequence data analysis. One unit of anti-
genic distance on an antigenic map corresponds to a
2-fold diﬀerence in the serological assay. Smith et al. (2)
use the periphery of each shape to denote an increase in
the error; here we use an outer circle to express the error
and an antigen point with larger circle indicates larger
uncertainty of its location. We note that the map can pres-
ent antigenic evolution only when the reference antisera
points are widely spread. In the case of human inﬂuenza
A/H3N2 viruses, Russell et al. (5) mentioned that ‘periods
of relative stasis lasting from 3 to 8 years were followed by
rapid antigenic changes’, which suggests that the antisera
data in a serological table should cover a period of more
than a decade in order to present antigenic evolution.
Since the serological data covering broad antigenicity
may not be always available from a single laboratory,
one of the illustrations on antigenic evolution in the fol-
lowing Example section uses combined serological data.
One of the main purposes of the Example section is to
show how antigenicity evolves based on serological data.
Note that the statement ‘serology data should cover more
than a decade to present antigenic evolution’ is only for
human inﬂuenza A/H3N2 viruses, not for other viruses
with higher evolutionary rates.
Figure 1. Overall ﬂowchart of ATIVS. (a) Example Data in the Serology Data. (b) Two supporting ﬁgures are performed by antigenicity analysis
based on the example in (a). (c) Antigenic map generated by the Example 3. (d) Screenshot of sequence data input.
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are human inﬂuenza A/H3N2 viruses, the serological data
analysis, in fact, can be applied to other inﬂuenza viruses
and animal viruses that can drift antigenically.
Sequence data analysis
In case antigenic distances can not be reliably provided by
serological data alone, we use sequence data to obtain
predicted antigenic distances. Based on the relationship
between the genetic diﬀerences and the antigenic dis-
tances, we proposed antigenic prediction models, which
have good agreement rates, for predicting antigenic var-
iants (3,4). These antigenic prediction models are now
incorporated into ATIVS. Sequence data analysis in
ATIVS allows one to input nucleotide or amino-acid
sequences of inﬂuenza A/H3N2 HA1 and to compare
these sequences against WHO-recommended vaccine
strains or other reference strains (as shown in
Figure 1d). In addition to upload nucleotide or amino-
acid sequences in FASTA format, ATIVS provides a
speciﬁc site mode where sequence sites and their corre-
sponding amino-acid residues are required for inputting
data. Furthermore, user-deﬁned colors encoded in RGB
color model can also be speciﬁed in this mode. An addi-
tional column with the title of COLOR is used to set up
the user-deﬁned colors. Using the amino-acid diﬀerences
between input strains and reference strains obtained
by ClustalW and the above model, ATIVS automatically
provides the predicted antigenic distances, which are
shown in a downloadable table. Then, the antigenicity
analysis can be performed as described before.
For antigen i and antiserum j, let Dij be the log2 of
the predicted antigenic distances of the input virus strain
i (antigen) to reference strain j (antiserum), and dij
denote the Euclidean distance between them in the map,
which are obtained by minimizing the error function
E ¼
P
ij eðDij,dijÞ, where eðDij,dijÞ¼ð Dij   dijÞ
2 when Dij
< threshold (default is 8); eðDij,dijÞ¼ð Dij   dijÞ
2 
gðDij   dijÞ, gðxÞ¼1=ð1 þ e 10xÞ when Dij   threshold.
The equations are modiﬁed from the error function in
Smith et al. (2). The antigenic map is then obtained by
applying the multidimensional scaling algorithm to dij.
Since sequence data of viruses are widely available, this
approach to generate antigenic map may facilitate eﬃcient
surveillance of inﬂuenza viruses.
In sequence data analysis, ATIVS allows users to
upload the maximum of 500 sequences and the results
can be obtained in a couple of minutes. However, since
the antigenic prediction models are only for human inﬂu-
enza A/H3N2 viruses, at least 50% sequence similarity to
HA1 is required for sequence data input.
EXAMPLES
We have created examples that demonstrate the function-
alities of the web server. Three examples are included
for the illustration of the use of serological data, and
one example is for the use of sequence data. Example 1
exhibits an ordinary HI table, in which the contemporary
vaccine strains and potential reference strains are
compared with the recent circulating viruses. Using the
two supporting ﬁgures, we know immediately which ref-
erence strains are suitable vaccine candidates. Example 2
uses an HI table of selected successive strains over 25
years, which shows how antigenicity evolves over a long
period from 1968 to 1997. In Example 3, we combine ﬁve
datasets, obtained at diﬀerent times, to form the
HI table (the detailed sources are shown in the website).
The antigenic map obtained from the combined data has a
high consistency with the map that was shown in the study
of Berkhoﬀ et al. except a spinning of 458 (6). As shown in
Figure 1c, the antigenic map demonstrates that the viruses
drifted from A/Beijing/353/89 to A/Beijing/32/92, to
A/Wuhan/353/95 and A/Sydney/5/97, to A/Fujian/411/
2002 then to A/California/7/2004, which is concordant
with the inﬂuenza epidemics (the high resolution ﬁgure
can be found in ATIVS). The two HI tables in Example
2 and Example 3, including over-decade reference strains,
can be used to generate antigenic maps which show con-
tinuous antigenic drift over a long period.
Example 4 uses sequence data to generate antigenic
map. Two hundred and ﬁfty-three sequences of speciﬁc
sites were extracted from the Supplementary Data
of Smith et al. (2). For each of the 11 clusters identiﬁed
by Smith et al., we randomly select one to three sequences
based on the size of the cluster. Twenty-ﬁve sequences
were accordingly selected and used as reference
strains. These sequence data are available in our website.
After sequence alignment with A/Brisbane/10/2007,
Figure 2. Antigenic map of inﬂuenza A/H3N2 viruses from 1968 to
2003 generated by ATIVS. The abbreviations and colors of the clusters
follow the deﬁnitions of Smith et al. (2).
Nucleic AcidsResearch, 2009, Vol.37, WebServer issue W645antigenic distances between each of the 253 strains
and each of the 25 reference strains are predicted and an
antigenic map is subsequently generated by the server.
This antigenic map (Figure 2) is highly consistent with
the Smith’s map, which shows the robustness of our
method.
CONCLUSIONS
ATIVS is a java-based web server built on Linux. Both
serology data of all inﬂuenza viruses and HA1 sequence
data of human inﬂuenza A/H3N2 viruses can be utilized
to generate antigenic maps that are useful in inﬂuenza
virus surveillance and vaccine strain selection.
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